On March 25, 2026, Kymera Therapeutics, Inc. announced an amendment to its Second Amended and Restated Bylaws. The amendment designates the federal district courts of the United States as the exclusive forum for resolving any complaints asserting causes of action under the Securities Act of 1933 and the Securities Exchange Act of 1934. This decision comes in response to recent changes in Delaware's General Corporation Law regarding forum selection provisions. The amendment is effective immediately and reflects the company's commitment to aligning its governance practices with evolving legal standards. The full text of the Bylaw Amendment is available as Exhibit 3.1 in the company's recent 8-K filing.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.